Research and Markets (http://www.researchandmarkets.com/research/tns8nf/juvenile) has announced the addition of the "Juvenile Rheumatoid Arthritis-Pipeline Insights, 2015" subscription to their offering.

This Juvenile Rheumatoid Arthritis-Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Juvenile Rheumatoid Arthritis.

This report provides information on the therapeutic development based on the Juvenile Rheumatoid Arthritis dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Key Topics Covered:

  1. Juvenile Rheumatoid Arthritis Overview
  2. Juvenile Rheumatoid Arthritis Pipeline Therapeutics
  3. Juvenile Rheumatoid Arthritis Therapeutics under Development by Companies
  4. Juvenile Rheumatoid Arthritis Late Stage Products (Filed and Phase III)
  5. Comparative Analysis
  6. Juvenile Rheumatoid Arthritis Mid Clinical Stage Products (Phase II)
  7. Comparative Analysis
  8. Juvenile Rheumatoid Arthritis Early Clinical Stage Products (Phase I and IND Filed)
  9. Comparative Analysis
  10. Juvenile Rheumatoid Arthritis Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Juvenile Rheumatoid Arthritis - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Juvenile Rheumatoid Arthritis - Discontinued Products
  19. Juvenile Rheumatoid Arthritis - Dormant Products
  20. Companies Involved in Therapeutics Development for Juvenile Rheumatoid Arthritis
  21. Appendix

For more information visit http://www.researchandmarkets.com/research/tns8nf/juvenile